Glenda Halliday

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7383115/publications.pdf

Version: 2024-02-01

700	72,038	813	983
papers	citations	118 h-index	237 g-index

728	728	728	47213
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
2	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	3.9	4,389
3	Parkinson disease. Nature Reviews Disease Primers, 2017, 3, 17013.	30.5	3,048
4	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
5	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorders, 2008, 23, 837-844.	3.9	1,779
6	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
7	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	3.9	1,033
8	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	7.7	978
9	Disease duration and the integrity of the nigrostriatal system in Parkinsonâ€™s disease. Brain, 2013, 136, 2419-2431.	7.6	965
10	Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Research Reviews, 1987, 12, 117-165.	9.0	873
11	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	7.6	873
12	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
13	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurology, The, 2009, 8, 1150-1157.	10.2	734
14	Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 2017, 18, 101-113.	10.2	711
15	Dementia with Lewy bodies. Lancet Neurology, The, 2004, 3, 19-28.	10.2	645
16	Missing pieces in the Parkinson's disease puzzle. Nature Medicine, 2010, 16, 653-661.	30.7	621
17	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
18	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 2002, 125, 391-403.	7.6	587

#	Article	IF	Citations
19	Evidence for Î±-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5308-17.	7.1	578
20	Clinicopathological correlates in frontotemporal dementia. Annals of Neurology, 2004, 56, 399-406.	5.3	549
21	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
22	The cerebral cortex is damaged in chronic alcoholics. Neuroscience, 1997, 79, 983-998.	2.3	474
23	Reduced glucocerebrosidase is associated with increased Î±-synuclein in sporadic Parkinsonâ€™s disease. Brain, 2014, 137, 834-848.	7.6	397
24	Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 2021, 7, 47.	30.5	391
25	Clinical correlates of selective pathology in the amygdala of patients with Parkinsonâ€™s disease. Brain, 2002, 125, 2431-2445.	7.6	383
26	Glia: Initiators and progressors of pathology in Parkinson's disease. Movement Disorders, 2011, 26, 6-17.	3.9	383
27	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
28	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 2014, 29, 454-462.	3.9	379
29	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	7.7	377
30	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
31	Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 51-60.	1.9	373
32	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr Î±â€synuclein mutation. Annals of Neurology, 2001, 49, 313-319.	5.3	364
33	Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica, 2011, 122, 187-204.	7.7	357
34	Survival in frontotemporal dementia. Neurology, 2003, 61, 349-354.	1.1	355
35	Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. Brain, 2000, 123, 141-154.	7.6	351
36	Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Annals of Neurology, 1990, 27, 373-385.	5.3	346

#	Article	IF	Citations
37	The progression of pathology in longitudinally followed patients with Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 115, 409-415.	7.7	337
38	Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Research, 1990, 510, 104-107.	2.2	320
39	The pathological basis of semantic dementia. Brain, 2005, 128, 1984-1995.	7.6	313
40	Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. Progress in Neurobiology, 2005, 75, 109-124.	5.7	313
41	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 2005, 128, 2665-2674.	7.6	307
42	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
43	An inflammatory review of Parkinsonâ€™s disease. Progress in Neurobiology, 2002, 68, 325-340.	5.7	297
44	The frontotemporal dementia-motor neuron disease continuum. Lancet, The, 2016, 388, 919-931.	13.7	294
45	Neuropathologic correlates of white matter hyperintensities. Neurology, 2008, 71, 804-811.	1.1	291
46	Alpha-synuclein biology in Lewy body diseases. Alzheimer's Research and Therapy, 2014, 6, 73.	6.2	288
47	The neurobiological basis of cognitive impairment in Parkinson's disease. Movement Disorders, 2014, 29, 634-650.	3.9	282
48	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. Brain, 2000, 123, 880-893.	7.6	277
49	Î±-Synucleinopathy phenotypes. Parkinsonism and Related Disorders, 2014, 20, S62-S67.	2.2	272
50	Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathologica, 2001, 102, 355-363.	7.7	262
51	PART is part of Alzheimer disease. Acta Neuropathologica, 2015, 129, 749-756.	7.7	256
52	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 2003, 60, 1005-1011.	1.1	247
53	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinsonâ€™s disease. Brain, 2014, 137, 2493-2508.	7.6	232
54	Language-Associated Cortical Regions Are Proportionally Larger in the Female Brain. Archives of Neurology, 1997, 54, 171-176.	4.5	224

#	Article	IF	Citations
55	Regional Specificity of Brain Atrophy in Huntington's Disease. Experimental Neurology, 1998, 154, 663-672.	4.1	224
56	Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei. Journal of Comparative Neurology, 2002, 445, 238-255.	1.6	223
57	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	7.7	222
58	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
59	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain, 2000, 123, 1410-1421.	7.6	219
60	The progression of pathology in Parkinson's disease. Annals of the New York Academy of Sciences, 2010, 1184, 188-195.	3.8	214
61	Monocyte Chemoattractant Proteinâ€1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease. Brain Pathology, 2009, 19, 392-398.	4.1	209
62	Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience, 1991, 42, 757-775.	2.3	202
63	Toll-like receptor 2 is increased in neurons in Parkinsonâ€™s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathologica, 2017, 133, 303-319.	7.7	200
64	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
65	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 865-870.	1.9	195
66	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
67	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 2005, 58, 829-839.	5.3	191
68	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. Genome Medicine, 2019, 11, 54.	8.2	191
69	Progression in Frontotemporal Dementia. Archives of Neurology, 2006, 63, 1627.	4.5	189
70	Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiology of Aging, 2014, 35, 858-866.	3.1	188
71	Î±-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 2005, 128, 2654-2664.	7.6	187
72	Inflammation is genetically implicated in Parkinsonâ€™s disease. Neuroscience, 2015, 302, 89-102.	2.3	182

#	Article	IF	Citations
73	Are Parkinsonâ€™s Disease with dementia and Dementia with lewy Bodies the Same Entity?. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 137-145.	2.3	180
74	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
75	c-Abl phosphorylates Î±-synuclein and regulates its degradation: implication for Î±-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Human Molecular Genetics, 2014, 23, 2858-2879.	2.9	176
76	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
77	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 1-8.	1.9	174
78	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
79	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1073-1083.	1.7	173
80	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	4.1	173
81	Brain shrinkage in alcoholics: a decade on and what have we learned?. Progress in Neurobiology, 1999, 58, 381-387.	5.7	172
82	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. Archives of Neurology, 2003, 60, 545.	4.5	172
83	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1601-1608.	3.9	171
84	Topography of brain atrophy during normal aging and alzheimer's disease. Neurobiology of Aging, 1996, 17, 513-521.	3.1	170
85	p25Î± Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy. American Journal of Pathology, 2007, 171, 1291-1303.	3.8	169
86	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degenerationâ€“motor neuron disease. Annals of Neurology, 2010, 68, 639-649.	5.3	168
87	Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. Neuroscience, 1999, 91, 429-438.	2.3	167
88	Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain, 2005, 128, 597-605.	7.6	167
89	The comparative biology of neuromelanin and lipofuscin in the human brain. Cellular and Molecular Life Sciences, 2008, 65, 1669-1682.	5.4	166
90	Degeneration of the centrï¿½ median-parafascicular complex in Parkinson's disease. Annals of Neurology, 2000, 47, 345-352.	5.3	165

#	Article	IF	Citations
91	Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. Journal of Comparative Neurology, 1996, 364, 121-150.	1.6	164
92	Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?. Movement Disorders, 2011, 26, 2154-2159.	3.9	164
93	Molecular Pathogenesis of the Tauopathies. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 239-261.	22.4	161
94	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathologica, 2002, 103, 370-376.	7.7	159
95	Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 2019, 15, 540-555.	10.1	159
96	Eating and hypothalamus changes in behavioralâ€variant frontotemporal dementia. Annals of Neurology, 2011, 69, 312-319.	5.3	158
97	Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology, 2012, 252, 95-99.	2.3	158
98	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimerâ€™s disease. Brain, 2012, 135, 3015-3025.	7.6	157
99	Tricks of the mind: Visual hallucinations as disorders of attention. Progress in Neurobiology, 2014, 116, 58-65.	5.7	156
100	Focal demyelination in Alzheimerâ€™s disease and transgenic mouse models. Acta Neuropathologica, 2010, 119, 567-577.	7.7	155
101	Structural heterogeneity of Î±-synuclein fibrils amplified from patient brain extracts. Nature Communications, 2019, 10, 5535.	12.8	153
102	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1033-1037.	1.9	151
103	Clinical Significance of Lobar Atrophy in Frontotemporal Dementia: Application of an MRI Visual Rating Scale. Dementia and Geriatric Cognitive Disorders, 2007, 23, 334-342.	1.5	150
104	Milestones in Parkinson's diseaseâ€”Clinical and pathologic features. Movement Disorders, 2011, 26, 1015-1021.	3.9	150
105	Chronic alcohol consumption does not cause hippocampal neuron loss in humans. , 1997, 7, 78-87.		148
106	Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses. Archives of Neurology, 2000, 57, 1586-91.	4.5	146
107	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1554-1563.	3.1	146
108	Cytoarchitecture of the human dorsal raphe nucleus. Journal of Comparative Neurology, 1990, 301, 147-161.	1.6	145

#	Article	IF	Citations
109	Parkinson's Disease Is Not Simply a Prion Disorder. Journal of Neuroscience, 2017, 37, 9799-9807.	3.6	144
110	Gutâ€“brain axis and the spread of Î±â€synuclein pathology: Vagal highway or dead end?. Movement Disorders, 2019, 34, 307-316.	3.9	144
111	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. PLoS ONE, 2011, 6, e17299.	2.5	142
112	Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience, 1996, 72, 699-708.	2.3	137
113	A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Structure and Function, 2012, 217, 591-612.	2.3	136
114	Regression in basal cell carcinoma: an immunohistochemical analysis. British Journal of Dermatology, 1994, 130, 1-8.	1.5	135
115	Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4⁺ T cells. World Journal of Surgery, 1995, 19, 352-358.	1.6	134
116	Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. Journal of Comparative Neurology, 1986, 252, 423-445.	1.6	133
117	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain, 2005, 128, 1259-1266.	7.6	133
118	Thalamic changes in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S152-S155.	2.2	132
119	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 2002, 125, 789-800.	7.6	126
120	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
121	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Movement Disorders, 2015, 30, 1639-1647.	3.9	123
122	Distribution of monoamine-synthesizing neurons in the human medulla oblongata. Journal of Comparative Neurology, 1988, 273, 301-317.	1.6	121
123	Localization of copper and copper transporters in the human brain. Metallomics, 2013, 5, 43-51.	2.4	121
124	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurology, The, 2016, 15, 332-342.	10.2	120
125	Biomarkers in dementia: clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1426-1434.	1.9	119
126	Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease. Experimental Neurology, 1997, 144, 202-213.	4.1	118

#	Article	IF	Citations
127	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Annals of Neurology, 2000, 47, 718-728.	5.3	116
128	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 747-751.	1.9	116
129	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. Neurobiology of Disease, 2015, 79, 81-99.	4.4	116
130	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain, 2003, 126, 814-826.	7.6	114
131	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534.	7.6	114
132	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	3.9	114
133	Variations in the neuropathology of familial Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 118, 37-52.	7.7	112
134	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Movement Disorders, 2014, 29, 518-526.	3.9	112
135	Selective loss of pyramidal neurons in the preâ€supplementary motor cortex in Parkinson's disease. Movement Disorders, 2002, 17, 1166-1173.	3.9	111
136	The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Human Brain Mapping, 2014, 35, 2206-2219.	3.6	111
137	Neuropathology of Î±â€synuclein propagation and braak hypothesis. Movement Disorders, 2016, 31, 152-160.	3.9	111
138	Changes in the solubility and phosphorylation of Î±-synuclein over the course of Parkinsonâ€™s disease. Acta Neuropathologica, 2011, 121, 695-704.	7.7	108
139	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.5	108
140	C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology, 2012, 79, 995-1001.	1.1	108
141	Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. British Journal of Dermatology, 2002, 146, 810-815.	1.5	107
142	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	7.7	107
143	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. Progress in Neurobiology, 2010, 92, 316-329.	5.7	106
144	Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1234-1241.	1.9	106

#	Article	IF	Citations
145	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathologica, 2004, 108, 515-523.	7.7	105
146	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	1.7	104
147	Cerebellar atrophy in Parkinsonâ€™s disease and its implication for network connectivity. Brain, 2016, 139, 845-855.	7.6	103
148	Pyramidal Cell Loss in Motor Cortices in Huntington's Disease. Neurobiology of Disease, 2002, 10, 378-386.	4.4	101
149	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain, 2005, 128, 2272-2280.	7.6	100
150	Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Annals of Neurology, 2001, 49, 313-9.	5.3	98
151	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
152	Variation in hippocampal neuron number with age and brain volume. Cerebral Cortex, 1998, 8, 710-718.	2.9	96
153	AÎ² and tau prion-like activities decline with longevity in the Alzheimerâ€™s disease human brain. Science Translational Medicine, 2019, 11, .	12.4	96
154	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathologica, 1992, 84, 638-50.	7.7	95
155	Quantification of cortical atrophy in a case of progressive fluent aphasia. Brain, 1996, 119, 181-190.	7.6	95
156	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain, 2015, 138, 3110-3122.	7.6	94
157	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. Journal of Clinical Neuroscience, 1996, 3, 52-60.	1.5	93
158	Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain, 2004, 127, 2214-2220.	7.6	93
159	pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	3.2	93
160	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica, 2010, 120, 777-788.	7.7	93
161	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
162	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Movement Disorders, 2002, 17, 133-137.	3.9	91

#	Article	IF	Citations
163	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathologica, 2006, 111, 329-340.	7.7	91
164	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	7.6	91
165	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. British Journal of Dermatology, 2011, 164, no-no.	1.5	90
166	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
167	SUBSTANCE P-CONTAINING NEURONS IN THE MESOPONTINE TEGMENTUM ARE SEVERELY AFFECTED IN PARKINSON'S DISEASE. Brain, 1991, 114, 2253-2267.	7.6	89
168	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica, 2012, 124, 373-382.	7.7	89
169	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. Metallomics, 2017, 9, 1447-1455.	2.4	89
170	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. British Journal of Dermatology, 2016, 175, 1073-1075.	1.5	88
171	Alphaâ€synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Reports, 2018, 19, .	4.5	88
172	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. Brain, 1999, 122, 675-686.	7.6	87
173	Pathology and hippocampal atrophy in Alzheimer's disease. Lancet Neurology, The, 2017, 16, 862-864.	10.2	87
174	Analysis of DNA methylation associates the cystineâ€“glutamate antiporter SLC7A11 with risk of Parkinsonâ€™s disease. Nature Communications, 2020, 11, 1238.	12.8	85
175	Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. Synapse, 1991, 7, 301-320.	1.2	84
176	Cytokine profiles in spontaneously regressing basal cell carcinomas. British Journal of Dermatology, 2000, 143, 91-98.	1.5	84
177	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 26697.	3.3	84
178	Clinicopathological Staging of Frontotemporal Dementia Severity: Correlation with Regional Atrophy. Dementia and Geriatric Cognitive Disorders, 2004, 17, 311-315.	1.5	83
179	Genetic contributions to Parkinson's disease. Brain Research Reviews, 2004, 46, 44-70.	9.0	83
180	Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. Biological Psychiatry, 2012, 71, 783-791.	1.3	83

#	Article	IF	Citations
181	LRRK2â€mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disorders, 2019, 34, 406-415.	3.9	83
182	Practical considerations for the use of the optical disector in estimating neuronal number. Journal of Neuroscience Methods, 1994, 51, 83-89.	2.5	82
183	Striatal Î²-amyloid in dementia with Lewy bodies but not Parkinsonâ€™s disease. Journal of Neural Transmission, 2011, 118, 713-719.	2.8	82
184	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	10.2	82
185	Reduced glucocerebrosidase activity in monocytes from patients with Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 15446.	3.3	82
186	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PLoS ONE, 2014, 9, e105632.	2.5	79
187	DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro. Movement Disorders, 2014, 29, 1606-1614.	3.9	79
188	Characterization of circular <scp>RNA</scp>s landscape in multiple system atrophy brain. Journal of Neurochemistry, 2016, 139, 485-496.	3.9	79
189	Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain, 2003, 126, 827-840.	7.6	78
190	Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2005, 232, 83-90.	0.6	78
191	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
192	ALS/FTLD: experimental models and reality. Acta Neuropathologica, 2017, 133, 177-196.	7.7	78
193	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinsonâ€™s disease brain. Acta Neuropathologica, 2017, 134, 113-127.	7.7	78
194	Parvalbumin as an anatomical marker for discrete subregions of the ambiguus complex in the rat. Neuroscience Letters, 1993, 160, 101-105.	2.1	77
195	Longitudinal white matter changes in frontotemporal dementia subtypes. Human Brain Mapping, 2014, 35, 3547-3557.	3.6	77
196	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinsonâ€™s disease. , 2006, , 99-103.		77
197	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2012, 520, 2591-2607.	1.6	76
198	An Improved Highâ€Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. Lipids, 2013, 48, 307-318.	1.7	76

#	Article	IF	Citations
199	Increased peripheral inflammation in asymptomatic leucineâ€rich repeat kinase 2 mutation carriers. Movement Disorders, 2016, 31, 889-897.	3.9	76
200	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.1	76
201	Autophagy activation promotes clearance of Î±-synuclein inclusions in fibril-seeded human neural cells. Journal of Biological Chemistry, 2019, 294, 14241-14256.	3.4	76
202	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. British Journal of Dermatology, 2009, 161, 1357-1364.	1.5	75
203	Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinsonâ€™s disease: a task-based fMRI study. Npj Parkinson's Disease, 2015, 1, 15003.	5.3	75
204	Psychiatric disorders in C9orf72 kindreds. Neurology, 2018, 91, e1498-e1507.	1.1	75
205	Temporal evolution of microglia and Î±-synuclein accumulation following foetal grafting in Parkinsonâ€™s disease. Brain, 2019, 142, 1690-1700.	7.6	75
206	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
207	Alpha-synuclein research: defining strategic moves in the battle against Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 65.	5.3	74
208	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. PLoS ONE, 2014, 9, e102909.	2.5	74
209	ParkinsonÃ¢â‚¬â„¢s disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience, 2014, 7, 57.	2.9	73
210	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Experimental Neurology, 2017, 298, 202-209.	4.1	73
211	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
212	Degeneration of the centrÃ© median-parafascicular complex in Parkinson's disease. Annals of Neurology, 2000, 47, 345-52.	5.3	73
213	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Movement Disorders, 2009, 24, 1519-1523.	3.9	72
214	Anti-melanin antibodies are increased in sera in Parkinson's disease. Experimental Neurology, 2009, 217, 297-301.	4.1	72
215	Eating behavior in frontotemporal dementia. Neurology, 2015, 85, 1310-1317.	1.1	72
216	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp>arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72

#	Article	IF	Citations
217	Physiological changes in neurodegeneration â€" mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271.	10.1	72
218	Pedigree with frontotemporal lobar degeneration â€“ motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurology, 2008, 8, 32.	1.8	71
219	Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2010, 36, 312-319.	3.2	70
220	Visual hallucinations in Parkinson's disease: Theoretical models. Movement Disorders, 2014, 29, 1591-1598.	3.9	70
221	AÎ²-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimerâ€™s disease. Nature Communications, 2015, 6, 8836.	12.8	70
222	MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathologica, 2018, 135, 49-63.	7.7	70
223	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2000, 57, 831.	4.5	69
224	Localization of immunoreactivity for Deleted in Colorectal Cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience, 2005, 131, 671-681.	2.3	69
225	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathologica Communications, 2015, 3, 47.	5.2	69
226	ABCA7 Mediates Phagocytic Clearance of Amyloid-Î² in the Brain. Journal of Alzheimer's Disease, 2016, 54, 569-584.	2.6	69
227	Brainstem Serotonergic Neurons in Chronic Alcoholics With and Without the Memory Impairment of KorsakoffÊ¼s Psychosis. Journal of Neuropathology and Experimental Neurology, 1993, 52, 567-579.	1.7	68
228	Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset AlzheimerÊ¼s disease. NeuroReport, 1998, 9, 3335-3339.	1.2	68
229	LRRK2 interactions with Î±-synuclein in Parkinsonâ€™s disease brains and in cell models. Journal of Molecular Medicine, 2013, 91, 513-522.	3.9	68
230	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp>lzheimer <scp>D</scp>isease <scp>N</scp>euroimaging <scp>I</scp>nitiative (<scp>ADNI</scp>) and the <scp>D</scp>ominantly <scp>I</scp>nherited <scp>A</scp>lzheimer <scp>N</scp>etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	1.2	68
231	Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. PLoS ONE, 2016, 11, e0157924.	2.5	68
232	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. Science Advances, 2022, 8, eabm5386.	10.3	68
233	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 817.	4.5	67
234	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. NeuroImage, 2007, 34, 1054-1059.	4.2	66

#	Article	IF	Citations
235	FTD and ALSâ€"translating mouse studies into clinical trials. Nature Reviews Neurology, 2015, 11, 360-366.	10.1	64
236	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. Expert Review of Neurotherapeutics, 2012, 12, 673-686.	2.8	63
237	Parkinsonâ€™s progression prediction using machine learning and serum cytokines. Npj Parkinson's Disease, 2019, 5, 14.	5.3	63
238	Î²-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 2006, 6, 6566-6577.	2.2	62
239	White matter loss in healthy ageing: A postmortem analysis. Neurobiology of Aging, 2009, 30, 1288-1295.	3.1	62
240	Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathologica Communications, 2014, 2, 150.	5.2	62
241	CYLD is a causative gene for frontotemporal dementia â€“ amyotrophic lateral sclerosis. Brain, 2020, 143, 783-799.	7.6	62
242	Corticobasal syndrome with tau pathology. Movement Disorders, 2001, 16, 656-667.	3.9	61
243	Identifying severely atrophic cortical subregions in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 797-806.	3.1	61
244	Dolichol is the major lipid component of human substantia nigra neuromelanin. Journal of Neurochemistry, 2005, 92, 990-995.	3.9	61
245	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathologica Communications, 2013, 1, 11.	5.2	61
246	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 2015, 130, 661-678.	7.7	61
247	Distribution of substance P-like immunoreactive neurons in the human medulla oblongata: Co-localization with monoamine-synthesizing neurons. Synapse, 1988, 2, 353-370.	1.2	60
248	The Subthalamic Nucleus in ParkinsonÊ¼s Disease and Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 1997, 56, 132-142.	1.7	60
249	Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience, 1997, 78, 641-652.	2.3	60
250	Pick bodies in a family with presenilin-1 Alzheimer's disease. Annals of Neurology, 2005, 57, 139-143.	5.3	60
251	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. NeuroImage: Clinical, 2017, 13, 439-445.	2.7	60
252	Transforming growth factor-Î² produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. International Immunology, 2001, 13, 1147-1154.	4.0	59

#	Article	IF	Citations
253	Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behavioural Brain Research, 2003, 139, 105-113.	2.2	59
254	Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata. Experimental Neurology, 1997, 144, 183-192.	4.1	58
255	The left human speech-processing cortex is thinner but longer than the right. Laterality, 2003, 8, 247-260.	1.0	58
256	Protective properties of lysozyme on Î²-amyloid pathology: implications for Alzheimer disease. Neurobiology of Disease, 2015, 83, 122-133.	4.4	58
257	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines. Acta Neuropathologica, 2019, 137, 437-454.	7.7	58
258	Idiopathic generalized epilepsy. Neurology, 2000, 55, 1101-1106.	1.1	57
259	Evidence for specific phases in the development of human neuromelanin. Neurobiology of Aging, 2006, 27, 506-512.	3.1	57
260	Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease. Experimental Neurology, 1996, 5, 49-55.	1.7	56
261	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. British Journal of Dermatology, 2006, 154, 72-78.	1.5	56
262	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. Movement Disorders, 2009, 24, 833-838.	3.9	56
263	Influence of Single Nucleotide Polymorphisms in <i>COMT</i>, <i>MAO-A</i> and <i>BDNF</i> Genes on Dyskinesias and Levodopa Use in Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 24-28.	1.4	56
264	Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. Translational Psychiatry, 2017, 7, e1003-e1003.	4.8	56
265	Parkinsonâ€™s Disease Subtypes: Critical Appraisal and Recommendations. Journal of Parkinson's Disease, 2021, 11, 395-404.	2.8	56
266	Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience, 1995, 68, 539-551.	2.3	54
267	Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. Acta Neuropathologica, 2002, 104, 72-78.	7.7	54
268	Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy. Journal of Biological Chemistry, 2003, 278, 6748-6754.	3.4	54
269	Variable phenotype of Alzheimerâ€™s disease with spastic paraparesis. Journal of Neurochemistry, 2008, 104, 573-583.	3.9	54
270	Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. Journal of Alzheimer's Disease, 2010, 22, 981-984.	2.6	54

#	Article	IF	Citations
271	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. Journal of Chemical Neuroanatomy, 2016, 76, 98-107.	2.1	54
272	Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity. , 1990, , 149-202.		54
273	Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. Neuroscience, 1995, 65, 87-91.	2.3	53
274	Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiology of Aging, 1998, 19, 297-306.	3.1	53
275	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neuroscience Letters, 2004, 361, 9-12.	2.1	53
276	Distribution of Pathology in Frontal Variant Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 63-70.	2.6	53
277	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain, 2020, 143, 31-46.	7.6	53
278	Selective hippocampal neuron loss in dementia with Lewy bodies. Annals of Neurology, 2002, 51, 125-128.	5.3	53
279	The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. Neuroscience, 1988, 26, 179-191.	2.3	52
280	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 531-538.	1.9	52
281	Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. Movement Disorders, 2006, 21, 632-638.	3.9	52
282	Lesion of thalamic centromedianâ€“ parafascicular complex after chronic deep brain stimulation. Neurology, 2001, 56, 1576-1579.	1.1	51
283	Circular RNAs: The Brain Transcriptome Comes Full Circle. Trends in Neurosciences, 2020, 43, 752-766.	8.6	51
284	Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathology and Applied Neurobiology, 1997, 23, 492-495.	3.2	50
285	A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism and Related Disorders, 2004, 10, 191-202.	2.2	50
286	Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Research Bulletin, 2009, 78, 97-104.	3.0	50
287	Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. Brain, 2014, 137, 2065-2076.	7.6	50
288	Dopamine depletion alters macroscopic network dynamics in Parkinsonâ€™s disease. Brain, 2019, 142, 1024-1034.	7.6	50

#	Article	IF	Citations
289	Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 2011, 32, 257-271.	3.1	49
290	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. Movement Disorders, 2012, 27, 1506-1512.	3.9	49
291	Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy, 2014, 10, 1350-1351.	9.1	49
292	Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathologica, 2019, 138, 705-727.	7.7	49
293	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
294	Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. Neuroscience Letters, 1996, 209, 29-32.	2.1	48
295	Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathologica, 2001, 101, 616-624.	7.7	48
296	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimers Disease. Current Alzheimer Research, 2011, 8, 765-770.	1.4	48
297	Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathologica Communications, 2013, 1, 33.	5.2	48
298	Systemic metabolism in frontotemporal dementia. Neurology, 2014, 83, 1812-1818.	1.1	48
299	Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. Journal of Neurology, 2016, 263, 1593-1603.	3.6	48
300	A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide Y in the ventrolateral medulla of rats, guinea-pigs and cats. Neuroscience, 1991, 43, 531-550.	2.3	47
301	The neural basis of semantic memory: Evidence from semantic dementia. Neurobiology of Aging, 2009, 30, 2043-2052.	3.1	47
302	Progression in Behavioral Variant Frontotemporal Dementia. JAMA Neurology, 2015, 72, 1501.	9.0	47
303	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. Journal of Alzheimer's Disease, 2017, 61, 773-783.	2.6	47
304	Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain. Synapse, 1993, 15, 1-16.	1.2	45
305	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. Movement Disorders, 2012, 27, 1262-1267.	3.9	45
306	Distinctive pathological mechanisms involved in primary progressiveÂaphasias. Neurobiology of Aging, 2016, 38, 82-92.	3.1	45

#	Article	IF	Citations
307	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging, 2013, 34, 873-886.	3.1	44
308	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. Journal of Parkinson's Disease, 2013, 3, 145-152.	2.8	44
309	Arylsulfatase A, a genetic modifier of Parkinsonâ€™s disease, is an Î±-synuclein chaperone. Brain, 2019, 142, 2845-2859.	7.6	44
310	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. Journal of Neurology, 2004, 251, 1098-104.	3.6	43
311	LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathologica, 2008, 116, 639-646.	7.7	43
312	Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Movement Disorders, 2011, 26, 256-263.	3.9	43
313	Can we clinically diagnose dementia with Lewy bodies yet?. Translational Neurodegeneration, 2013, 2, 4.	8.0	43
314	Abolishing the 1â€year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	3.9	43
315	Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. Brain Research, 1988, 461, 75-86.	2.2	42
316	Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathologica, 2000, 99, 199-208.	7.7	42
317	Clinical phenotypes in autopsy-confirmed Pick disease. Neurology, 2011, 76, 253-259.	1.1	42
318	Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Research Bulletin, 1989, 22, 725-735.	3.0	41
319	Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience, 1990, 39, 81-96.	2.3	41
320	Neurof ibrillary tangles in chronic alcoholics. Neuropathology and Applied Neurobiology, 1995, 21, 312-318.	3.2	41
321	The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 315-320.	1.9	41
322	A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain, 2000, 123, 724-732.	7.6	41
323	What is the dominant aÎ² species in human brain tissue? A review. Neurotoxicity Research, 2005, 7, 29-41.	2.7	41
324	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	1.7	41

#	Article	IF	Citations
325	Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm. Movement Disorders, 2012, 27, 500-505.	3.9	41
326	Earlyâ€onset axonal pathology in a novel <scp>P</scp>301<scp>S</scp>â€<scp>T</scp>au transgenic mouse model of frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2015, 41, 906-925.	3.2	41
327	Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts. Frontiers in Aging Neuroscience, 2016, 8, 274.	3.4	41
328	ABCA8 stimulates sphingomyelin production in oligodendrocytes. Biochemical Journal, 2013, 452, 401-410.	3.7	40
329	Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. PLoS ONE, 2013, 8, e78480.	2.5	40
330	ABCA5 Regulates Amyloid-Î² Peptide Production and is Associated with Alzheimer's Disease Neuropathology. Journal of Alzheimer's Disease, 2014, 43, 857-869.	2.6	40
331	Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathologica Communications, 2014, 2, 15.	5.2	40
332	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188.	4.4	40
333	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 486-495.	3.7	40
334	The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. Brain Research, 1992, 598, 33-37.	2.2	39
335	Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathologica, 1995, 90, 68-75.	7.7	39
336	Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology, 2001, 56, 944-950.	1.1	39
337	Human-based studies on Î±-synuclein deposition and relationship to Parkinson's disease symptoms. Experimental Neurology, 2008, 209, 12-21.	4.1	39
338	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. Journal of Alzheimer's Disease, 2010, 21, 193-205.	2.6	39
339	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	10.8	39
340	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Movement Disorders, 2017, 32, 423-432.	3.9	39
341	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
342	Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Scientific Reports, 2020, 10, 3640.	3.3	39

#	Article	IF	Citations
343	Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathology and Applied Neurobiology, 1998, 24, 195-201.	3.2	38
344	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. Experimental Neurology, 1999, 158, 135-142.	4.1	38
345	Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. British Journal of Dermatology, 2006, 155, 408-415.	1.5	38
346	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.7	38
347	Assessment of amyloid Î² in pathologically confirmed frontotemporal dementia syndromes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 10-20.	2.4	38
348	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
349	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. Neurobiology of Disease, 2002, 9, 249-257.	4.4	37
350	Topical Retinoic Acid Enhances, and a Dark Tan Protects, from Subedemal Solar-Simulated Photocarcinogenesis. Journal of Investigative Dermatology, 2000, 114, 923-927.	0.7	36
351	An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 2012, 40, 1134-1139.	3.4	36
352	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Brain, 2018, 141, 486-495.	7.6	36
353	Lipidomics Analysis of Behavioral Variant Frontotemporal Dementia: A Scope for Biomarker Development. Frontiers in Neurology, 2018, 9, 104.	2.4	36
354	Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. Movement Disorders, 2019, 34, 1374-1380.	3.9	36
355	Rostrocaudal differences in morphology and neurotransmitter content of cells in the subretrofacial vasomotor nucleus. Journal of the Autonomic Nervous System, 1992, 38, 117-137.	1.9	35
356	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Movement Disorders, 1999, 14, 626-633.	3.9	35
357	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. Neurology, 2004, 63, 1613-1617.	1.1	35
358	Evidence for specific phases in the development of human neuromelanin. Journal of Neural Transmission, 2006, 113, 721-728.	2.8	35
359	Phosphorylation of soluble tau differs in Pickâ€™s disease and Alzheimerâ€™s disease brains. Journal of Neural Transmission, 2009, 116, 1243-1251.	2.8	35
360	Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. Metabolic Brain Disease, 1995, 10, 81-91.	2.9	34

#	Article	IF	Citations
361	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. Neuropathology and Applied Neurobiology, 2006, 32, 374-387.	3.2	34
362	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. Movement Disorders, 2007, 22, 982-989.	3.9	34
363	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiology of Disease, 2004, 15, 115-119.	4.4	33
364	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 2012, 210, 363-374.	2.3	33
365	Exploring Myelin Dysfunction in Multiple System Atrophy. Experimental Neurobiology, 2014, 23, 337-344.	1.6	33
366	Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. Neurogenetics, 2015, 16, 107-122.	1.4	33
367	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). Neurobiology of Disease, 2015, 82, 445-454.	4.4	33
368	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitinâ€“proteasomal system and is present in the pathological features of parkinsonian diseases. Neurobiology of Disease, 2007, 27, 238-247.	4.4	32
369	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 831-838.	2.4	32
370	Serotonergic markers in Parkinson's disease and levodopaâ€induced dyskinesias. Movement Disorders, 2015, 30, 796-804.	3.9	32
371	Inhibitor treatment of peripheral mononuclear cells from Parkinsonâ€™s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 2016, 6, 31391.	3.3	32
372	Dementia in long-term Parkinsonâ€™s disease patients: a multicentre retrospective study. Npj Parkinson's Disease, 2020, 6, 2.	5.3	32
373	PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 612476.	3.7	32
374	Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer??s disease. NeuroReport, 2002, 13, 601-604.	1.2	31
375	The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Experimental Neurology, 2003, 184, 530-535.	4.1	31
376	Genetically confirmed clinical Huntington's disease with no observable cell loss. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 968-970.	1.9	31
377	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 387-393.	3.1	31
378	Cognitive, Extrapyramidal, and Magnetic Resonance Imaging Predictors of Functional Impairment in Nondemented Older Community Dwellers: The Sydney Older Person Study. Journal of the American Geriatrics Society, 2006, 54, 3-10.	2.6	31

#	Article	IF	Citations
379	Selective loss of oxytocin and vasopressin in the hypothalamus in early <scp>H</scp>untington disease: a case study. Neuropathology and Applied Neurobiology, 2015, 41, 843-848.	3.2	31
380	SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. Neuropathology and Applied Neurobiology, 2019, 45, 361-379.	3.2	31
381	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
382	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2021, 47, 979-989.	3.2	31
383	Control of Langerhans' cell density by a skin tumour-derived cytokine. Immunology, 1992, 77, 13-8.	4.4	31
384	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	30
385	Regional Brain Atrophy in Idiopathic Parkinson's Disease and Diffuse Lewy Body Disease. Dementia and Geriatric Cognitive Disorders, 1996, 7, 304-313.	1.5	30
386	Chronic Alcoholics without Wernicke-Korsakoff Syndrome or Cirrhosis Do Not Lose Serotonergic Neurons in the Dorsal Raphe Nucleus. Alcoholism: Clinical and Experimental Research, 1996, 20, 61-66.	2.4	30
387	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. International Journal of Geriatric Psychiatry, 2006, 21, 171-179.	2.7	30
388	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. Journal of Alzheimer's Disease, 2017, 58, 701-709.	2.6	30
389	Immune responses in the Parkinson's disease brain. Neurobiology of Disease, 2022, 168, 105700.	4.4	30
390	Preliminary Evidence Suggesting Delayed Development in the Hypoglossal and Vagal Nuclei of SIDS Infants: A Necropsy Study. Journal of Child Neurology, 1992, 7, 44-49.	1.4	29
391	Changes in Sphingomyelin Level Affect Alpha-Synuclein and ABCA5 Expression. Journal of Parkinson's Disease, 2012, 2, 41-46.	2.8	29
392	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. Annals of Neurology, 2016, 79, 295-305.	5.3	29
393	Accelerated aging exacerbates a preâ€existing pathology in a tau transgenic mouse model. Aging Cell, 2017, 16, 377-386.	6.7	29
394	Î±-Synuclein Regulates Neuronal Cholesterol Efflux. Molecules, 2017, 22, 1769.	3.8	29
395	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
396	The underacknowledged PPA-ALS. Neurology, 2019, 92, e1354-e1366.	1.1	29

#	Article	IF	Citations
397	Apolipoprotein D Upregulation in Alzheimerâ€™s Disease but Not Frontotemporal Dementia. Journal of Molecular Neuroscience, 2019, 67, 125-132.	2.3	29
398	Catecholaminergic Neurons. , 1990, , 1023-1049.		29
399	Serotonin and alcohol-related brain damage. Metabolic Brain Disease, 1995, 10, 25-30.	2.9	28
400	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. Journal of Neurochemistry, 2005, 95, 599-608.	3.9	28
401	Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitroâ€. Biochemistry, 2005, 44, 7346-7353.	2.5	28
402	Srp20 regulates TrkB preâ€mRNA splicing to generate TrkBâ€Shc transcripts with implications for Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 123, 159-171.	3.9	28
403	FAS-Dependent Cell Death in Î±-Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. PLoS ONE, 2013, 8, e55243.	2.5	28
404	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. PLoS ONE, 2014, 9, e87119.	2.5	28
405	Validation of the Psychosis and Hallucinations Questionnaire in Nonâ€demented Patients with Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 175-181.	1.5	28
406	Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. Parkinsonism and Related Disorders, 2016, 24, 89-94.	2.2	28
407	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. Neuroscience, 2018, 374, 326-334.	2.3	28
408	Chronic traumatic encephalopathy in two former Australian National Rugby League players. Acta Neuropathologica Communications, 2019, 7, 97.	5.2	28
409	Targeted, High-Resolution RNA Sequencing of Non-coding Genomic Regions Associated With Neuropsychiatric Functions. Frontiers in Genetics, 2019, 10, 309.	2.3	28
410	Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neuroscience Letters, 1997, 227, 49-52.	2.1	27
411	Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. Neuropathology and Applied Neurobiology, 2006, 32, 83-91.	3.2	27
412	Excessive dopamine neuron loss in progressive supranuclear palsy. Movement Disorders, 2008, 23, 607-610.	3.9	27
413	Utility and Limitations of Addenbrookeâ€™s Cognitive Examination-Revised for Detecting Mild Cognitive Impairment in Parkinsonâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2011, 31, 349-357.	1.5	27
414	Heritability in frontotemporal dementia: more missing pieces?. Journal of Neurology, 2014, 261, 2170-2177.	3.6	27

#	Article	IF	Citations
415	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2017, 5, 76.	5.2	27
416	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
417	Protein kinase C transduces the signal for Langerhans' cell migration from the epidermis. Immunology, 1993, 79, 621-6.	4.4	27
418	Effect of Chronic Alcohol Consumption on the Human Locus Coeruleus. Alcoholism: Clinical and Experimental Research, 1994, 18, 1491-1496.	2.4	26
419	New face of neuromelanin. , 2006, , 119-123.		26
420	Antigen-Epitope Retrieval To Facilitate Proteomic Analysis of Formalin-Fixed Archival Brain Tissue. Analytical Chemistry, 2006, 78, 7216-7221.	6.5	26
421	Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 117, 19-29.	7.7	26
422	Pathological Staging of Frontotemporal Lobar Degeneration. Journal of Molecular Neuroscience, 2011, 45, 379-383.	2.3	26
423	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	3.3	26
424	Similar early clinical presentations in familial and non-familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1743-1745.	1.9	25
425	Pallidal stimulation reduces treatmentâ€induced dyskinesias in â€œminimalâ€•changeâ€•multiple system atrophy. Movement Disorders, 2005, 20, 1042-1047.	3.9	25
426	P25Î± immunoreactive but Î±-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathologica, 2006, 111, 193-195.	7.7	25
427	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neuroscience, 2010, 11, 23.	1.9	25
428	Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. British Journal of Dermatology, 2012, 167, 631-636.	1.5	25
429	DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. Neuroscience Bulletin, 2013, 29, 649-654.	2.9	25
430	High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. Molecular Brain, 2015, 8, 2.	2.6	25
431	Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain, 2022, 145, 3108-3130.	7.6	25
432	Lipid pathway dysfunction is prevalent in patients with Parkinsonâ€™s disease. Brain, 2022, 145, 3472-3487.	7.6	25

#	Article	IF	Citations
433	Severe Anterograde Amnesia with Extensive Hippocampal Degeneration in a Case of Rapidly Progressive Frontotemporal Dementia.. Neurocase, 2001, 7, 57-64.	0.6	24
434	Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 956-958.	1.9	24
435	Effect of age on proliferationâ€regulating factors in human adult neurogenic regions. Journal of Neurochemistry, 2010, 115, 956-964.	3.9	24
436	The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 2010, 6, 175-179.	10.1	24
437	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T Î±-synuclein mutation. Translational Neurodegeneration, 2012, 1, 2.	8.0	24
438	Frontotemporal dementiaâ€“amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1â€“q12.2: genetic, clinical and neuropathological analysis. Acta Neuropathologica, 2013, 125, 523-533.	7.7	24
439	Retrosplenial Cortex (BA 29) Volumes in Behavioral Variant Frontotemporal Dementia and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2013, 35, 177-182.	1.5	24
440	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. Neurobiology of Learning and Memory, 2016, 130, 34-43.	1.9	24
441	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. Neuroscience, 2016, 322, 234-250.	2.3	24
442	Levels of glial cell lineâ€derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinsonâ€™s disease. Brain Pathology, 2019, 29, 813-825.	4.1	24
443	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. Neurology, 2021, 96, e1743-e1754.	1.1	24
444	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain, 2002, 125, 789-800.	7.6	24
445	Substantia Nigra and Locus Coeruleus. , 2004, , 449-463.		23
446	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Movement Disorders, 2009, 24, 290-292.	3.9	23
447	Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. , 2012, , 439-455.		23
448	Terra incognitaâ€”cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. Frontiers in Aging Neuroscience, 2015, 7, 121.	3.4	23
449	Aneuploidy in Lewy body diseases. Neurobiology of Aging, 2015, 36, 1253-1260.	3.1	23
450	ROCK1 Is Associated with Alzheimerâ€™s Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic AÎ² Clearance. Frontiers in Cellular Neuroscience, 2016, 10, 253.	3.7	23

#	Article	IF	Citations
451	Expanding the phenotypic associations of globular glial tau subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 6-13.	2.4	23
452	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	6.1	23
453	Accumulation of dysfunctional SOD1 protein in Parkinsonâ€™s disease is not associated with mutations in the SOD1 gene. Acta Neuropathologica, 2018, 135, 155-156.	7.7	23
454	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
455	Defining early changes in Alzheimerâ€™s disease from RNA sequencing of brain regions differentially affected by pathology. Scientific Reports, 2021, 11, 4865.	3.3	23
456	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Movement Disorders, 2021, 36, 2085-2093.	3.9	23
457	Reproducible sampling regimen for specific cortical regions: application to speech-associated areas. Journal of Neuroscience Methods, 1996, 67, 43-51.	2.5	22
458	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Movement Disorders, 2005, 20, 34-39.	3.9	22
459	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. Journal of Alzheimer's Disease, 2012, 30, 35-39.	2.6	22
460	Cross-examining candidate genes implicated in multiple system atrophy. Acta Neuropathologica Communications, 2019, 7, 117.	5.2	22
461	Predictors of survival and progression in behavioural variant frontotemporal dementia. European Journal of Neurology, 2019, 26, 774-779.	3.3	22
462	The dorsal, posterodorsal, and ventral tegmental nuclei: A cyto- and chemoarchitectonic study in the human. Journal of Comparative Neurology, 1992, 318, 117-137.	1.6	21
463	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		21
464	Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement: Figure 1. Brain, 2015, 138, 2116-2119.	7.6	21
465	Four groups of tyrosine hydroxylase-immunoreactive neurons in the ventrolateral medulla of rats, guinea-pigs and cats identified on the basis of chemistry, topography and morphology. Neuroscience, 1991, 43, 551-568.	2.3	20
466	Regulation of the Skin Immune System by Retinoids During Carcinogenesis. Journal of Investigative Dermatology, 1992, 99, S83-S86.	0.7	20
467	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders, 2013, 28, 1351-1359.	3.9	20
468	The relationships between mild cognitive impairment and phenotype in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2015, 1, 15015.	5.3	20

#	Article	IF	Citations
469	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. Journal of Alzheimer's Disease, 2017, 61, 705-715.	2.6	20
470	Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. Neurobiology of Disease, 2019, 130, 104524.	4.4	20
471	TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology, 2019, 93, e1748-e1755.	1.1	20
472	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. Acta Neuropathologica Communications, 2020, 8, 76.	5.2	20
473	Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. Molecular Psychiatry, 2021, 26, 6880-6895.	7.9	20
474	Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. Journal of Chemical Neuroanatomy, 1992, 5, 311-313.	2.1	19
475	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. Experimental Neurology, 1996, 5, 177-187.	1.7	19
476	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 503-511.	3.2	19
477	The relationship between clinical and pathological variables in Richardsonâ€™s syndrome. Journal of Neurology, 2012, 259, 482-490.	3.6	19
478	Increased Expression of ABCA8 in Multiple System Atrophy Brain is Associated with Changes in Pathogenic Proteins. Journal of Parkinson's Disease, 2013, 3, 331-339.	2.8	19
479	Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease. PLoS ONE, 2016, 11, e0160501.	2.5	19
480	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2018, 58, 70-74.	1.5	19
481	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2019, 78, 605-614.	1.7	19
482	Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both AÎ² and tau pathology. Neurobiology of Aging, 2020, 89, 129-131.	3.1	19
483	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. Journal of Sleep Research, 2020, 29, e12939.	3.2	19
484	Effect of inhibitors of oxygen radical and nitric oxide formation on UV radiation-induced erythema, immunosuppression and carcinogenesis. Redox Report, 1999, 4, 316-319.	4.5	18
485	Clinical and Neuropathological Abnormalities in Baboons Treated with HPTP, the Tetrahydropyridine Analog of Haloperidol. Experimental Neurology, 1999, 158, 155-163.	4.1	18
486	Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. British Journal of Dermatology, 2004, 151, 42-49.	1.5	18

#	Article	IF	Citations
487	VISAâ€"A pass to innate immunity. International Journal of Biochemistry and Cell Biology, 2007, 39, 287-291.	2.8	18
488	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. Neurogenetics, 2015, 16, 201-213.	1.4	18
489	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimerâ€™s disease and not in other tauopathies. Acta Neuropathologica Communications, 2019, 7, 195.	5.2	18
490	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. Journal of Neuroinflammation, 2021, 18, 177.	7.2	18
491	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. Npj Parkinson's Disease, 2022, 8, 34.	5.3	18
492	A Comparative Study of Avidin-Biotin-Peroxidase Complexes for the Immunohistochemical Detection of Antigens in Neural Tissue. Biotechnic and Histochemistry, 1992, 67, 367-371.	1.3	17
493	Alzheimer's disease: Its diagnosis and pathogenesis. International Review of Neurobiology, 2001, 48, 167-217.	2.0	17
494	Neuropathology in the S305S tau gene mutation. Brain, 2006, 129, E40-E40.	7.6	17
495	Haplotype analysis of the IGF2â€INSâ€TH gene cluster in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 495-499.	1.7	17
496	Clinical correlates of similar pathologies in parkinsonian syndromes. Movement Disorders, 2011, 26, 499-506.	3.9	17
497	Aspects of Innate Immunity and Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2012, 3, 33.	3.5	17
498	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2013, 1, 30.	5.2	17
499	Pathway Analysis of the Human Brain Transcriptome in Disease. Journal of Molecular Neuroscience, 2013, 51, 28-36.	2.3	17
500	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. PLoS ONE, 2013, 8, e74016.	2.5	17
501	Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 58, 163-170.	2.6	17
502	Heritability in frontotemporal tauopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 115-124.	2.4	17
503	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. Journal of Neurology, 2020, 267, 380-389.	3.6	17
504	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	7.6	17

#	Article	IF	Citations
505	The midbrain dopaminergic cell groups in the baboon papio ursinus. Brain Research Bulletin, 1998, 47, 611-623.	3.0	16
506	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 688-695.	1.0	16
507	DATâ€SPECT diagnoses dopamine depletion, but not PD. Movement Disorders, 2014, 29, 1705-1706.	3.9	16
508	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 175-185.	2.8	16
509	SNCAGene, but NotMAPT, Influences Onset Age of Parkinsonâ€™s Disease in Chinese and Australians. BioMed Research International, 2015, 2015, 1-6.	1.9	16
510	IsCHCHD10Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?: Figure 1. Brain, 2015, 138, e385-e385.	7.6	16
511	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. British Journal of Dermatology, 2016, 175, 1363-1365.	1.5	16
512	Animal modeling an oligodendrogliopathy â€“ multiple system atrophy. Acta Neuropathologica Communications, 2016, 4, 12.	5.2	16
513	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. Frontiers in Neuroscience, 2018, 12, 847.	2.8	16
514	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiology of Disease, 2018, 120, 76-87.	4.4	16
515	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. Neurology, 2019, 92, e2472-e2482.	1.1	16
516	The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 310-316.	1.7	16
517	Tackling clinical heterogeneity across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum using a transdiagnostic approach. Brain Communications, 2021, 3, fcab257.	3.3	16
518	Tenuigenin Attenuates Î±â€Synucleinâ€Induced Cytotoxicity by Downâ€Regulating Poloâ€Like Kinase 3. CNS Neuroscience and Therapeutics, 2013, 19, 688-694.	3.9	15
519	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
520	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2021, 11, 1761-1772.	2.8	15
521	Comparison of the Number of Vasopressin-Producing Hypothalamic Neurons in Rats and Humans. Journal of Neuroendocrinology, 1995, 7, 629-636.	2.6	14
522	A 6-Year Study of Cognition and Spatial Function in the Demented and Non-Demented Elderly: The Sydney Older Persons Study. Dementia and Geriatric Cognitive Disorders, 2003, 16, 181-186.	1.5	14

#	Article	IF	Citations
523	Interaction between Î±-Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 271-276.	2.8	14
524	Alpha-synuclein: prion or prion-like?. Acta Neuropathologica, 2019, 138, 509-514.	7.7	14
525	Brain Banking for Research into Neurodegenerative Disorders and Ageing. Neuroscience Bulletin, 2019, 35, 283-288.	2.9	14
526	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Communications Medicine, 2021, 1, .	4.2	14
527	Identification of families with cortical Lewy body disease. American Journal of Medical Genetics Part A, 2004, 128B, 118-122.	2.4	13
528	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. Movement Disorders, 2009, 24, 2128-2135.	3.9	13
529	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	3.9	13
530	Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. Brain, 2010, 133, e158-e158.	7.6	13
531	Leucineâ€rich repeat kinase 2 and alternative splicing in Parkinson's disease. Movement Disorders, 2012, 27, 1004-1011.	3.9	13
532	Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging, 2013, 34, 2235.e11-2235.e13.	3.1	13
533	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
534	Early white matter pathology in the fornix of the limbic system in Huntington disease. Acta Neuropathologica, 2021, 142, 791-806.	7.7	13
535	Brain stem nuclei in sudden infant death syndrome (SIDS): volumes, neuronal numbers and positions. Neuropathology and Applied Neurobiology, 1995, 21, 262-268.	3.2	12
536	Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. Metabolic Brain Disease, 1996, 11, 217-227.	2.9	12
537	Parkinson's disease with late Pick's dementia. Movement Disorders, 2001, 16, 311-319.	3.9	12
538	Role of hippocalcin in mediating AÎ² toxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1247-1257.	3.8	12
539	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
540	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12060.	3.7	12

#	Article	IF	Citations
541	The Neural Signature of Impaired <scp>Dualâ€Tasking</scp> in Idiopathic Rapid Eye Movement Sleep Behavior Disorder Patients. Movement Disorders, 2020, 35, 1596-1606.	3.9	12
542	Accelerated loss of hypoxia response in zebrafish with familial Alzheimerâ€™s disease-like mutation of presenilin 1. Human Molecular Genetics, 2020, 29, 2379-2394.	2.9	12
543	Neuropathological correlates of memory dysfunction in the Wernicke-Korsakoff syndrome. Alcohol and Alcoholism Supplement, 1994, 2, 245-51.	0.0	12
544	Electron microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. Journal of Comparative Neurology, 1984, 230, 393-412.	1.6	11
545	Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. Journal of Neuroscience Methods, 1996, 64, 83-93.	2.5	11
546	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. Movement Disorders, 2004, 19, 709-711.	3.9	11
547	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. Neuropathology and Applied Neurobiology, 2007, 33, 328-333.	3.2	11
548	The midbrainâ€toâ€pons ratio distinguishes progressive supranuclear palsy from nonâ€fluent primary progressive aphasias. European Journal of Neurology, 2017, 24, 956-965.	3.3	11
549	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032-1033.	10.2	11
550	Reply: LATE to the PART-y. Brain, 2019, 142, e48-e48.	7.6	11
551	Impaired Color Discriminationâ€”A Specific Marker of Hallucinations in Lewy Body Disorders. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 257-264.	2.3	11
552	Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain. Frontiers in Neuroscience, 2019, 13, 1187.	2.8	11
553	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALSâ€FTD spectrum. Annals of Clinical and Translational Neurology, 2021, 8, 1576-1591.	3.7	11
554	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinsonâ€™s Disease Patient Monocytes and Inversely Correlates with Motor Severity. Journal of Parkinson's Disease, 2021, 11, 1157-1165.	2.8	11
555	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. Neurology, 2021, 97, e1031-e1040.	1.1	11
556	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. Journal of Alzheimer's Disease, 2021, 84, 1153-1161.	2.6	11
557	Parkinsonism and cerebrovascular disease. Journal of the Neurological Sciences, 2022, 433, 120011.	0.6	11
558	Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. Scientific Reports, 2021, 11, 21348.	3.3	11

#	Article	IF	Citations
559	Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. Brain Research Bulletin, 1988, 21, 659-670.	3.0	10
560	Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. Life Sciences, 2000, 66, 1345-1350.	4.3	10
561	The Serotonin and Tachykinin Systems. , 2004, , 1205-1256.		10
562	Insoluble Î±-synuclein in alzheimerâ€™s disease without lewy body formation. Neurotoxicity Research, 2005, 7, 69-76.	2.7	10
563	Investigation of the lipid component of neuromelanin. Journal of Neural Transmission, 2006, 113, 735-739.	2.8	10
564	Clarifying the pathological progression of Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 115, 377-378.	7.7	10
565	Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. DMM Disease Models and Mechanisms, 2013, 6, 1198-204.	2.4	10
566	Prodegenerative IºBÎ± expression in oligodendroglial Î±-synuclein models of multiple system atrophy. Neurobiology of Disease, 2014, 63, 171-183.	4.4	10
567	The role of transcriptional control in multiple system atrophy. Neurobiology of Aging, 2015, 36, 394-400.	3.1	10
568	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2016, 366, 197-201.	0.6	10
569	Clinical Aspects of Alzheimerâ€™s Disease. Advances in Neurobiology, 2017, 15, 31-53.	1.8	10
570	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. ENeuro, 2018, 5, ENEURO.0234-18.2018.	1.9	10
571	CNS cell typeâ€“specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162.	3.4	10
572	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 963-967.	2.6	10
573	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 2020, 144, 105049.	4.4	10
574	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
575	Thalmic vaciuation in acute Wernicke's encephalopathy. Metabolic Brain Disease, 1993, 8, 107-113.	2.9	9
576	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 2007, 414, 170-173.	2.1	9

#	Article	IF	Citations
577	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2018, 44, 522-532.	3.2	9
578	Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. Frontiers in Psychology, 2018, 9, 1615.	2.1	9
579	Hypothalamic symptoms of frontotemporal dementia disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 269-280.	1.8	9
580	Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimerâ€™s disease. Current Alzheimer Research, 2015, 12, 745-751.	1.4	9
581	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	7.6	9
582	Neurofilament-Immunoreactive Neurons Are Not Selectively Vulnerable in Alzheimer's Disease. Neurobiology of Disease, 2001, 8, 136-146.	4.4	8
583	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 196-205.	2.3	8
584	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. American Journal of Pathology, 2018, 188, 1447-1456.	3.8	8
585	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 162-171.	1.9	8
586	Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathologica, 1995, 90, 68-75.	7.7	8
587	Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. Scientific Reports, 2022, 12, 40.	3.3	8
588	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. Australian and New Zealand Journal of Psychiatry, 1997, 31, 27-35.	2.3	7
589	Tau isoform expression in frontotemporal dementia without tau deposition. Journal of Clinical Neuroscience, 2007, 14, 1182-1185.	1.5	7
590	Clinicopathological aspects of motor parkinsonism. Parkinsonism and Related Disorders, 2007, 13, S208-S210.	2.2	7
591	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology, 2011, 43, 93-102.	0.6	7
592	An evidence base for noradrenergic deficits in Parkinson's disease. Movement Disorders, 2012, 27, 1589-1591.	3.9	7
593	Earlyâ€life decline in neurogenesis markers and ageâ€related changes of TrkB splice variant expression in the human subependymal zone. European Journal of Neuroscience, 2017, 46, 1768-1778.	2.6	7
594	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 333-339.	2.3	7

#	Article	IF	Citations
595	Prodromal neuroinvasion of pathological Î±-synuclein in brainstem reticular nuclei and white matter lesions in a model of Î±-synucleinopathy. Brain Communications, 2021, 3, fcab104.	3.3	7
596	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. Neurobiology of Disease, 2021, 157, 105426.	4.4	7
597	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. Journal of Histotechnology, 1996, 19, 33-38.	0.5	6
598	NORADRENERGIC LOCUS COERULEUS NEURONS. Alcoholism: Clinical and Experimental Research, 1996, 20, 191-192.	2.4	6
599	Unilateral rest tremor in vascular parkinsonism associated with a contralateral lesion of the locus coeruleus. Movement Disorders, 2009, 24, 1242-1244.	3.9	6
600	Pathology of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 132-154.	0.1	6
601	The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiology of Disease, 2020, 145, 105082.	4.4	6
602	Alzheimer's amyloidâ€Î² and tau protein accumulation is associated with decreased expression of the LDL receptorâ€associated protein in human brain tissue. Brain and Behavior, 2020, 10, e01672.	2.2	6
603	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 2192-2199.	3.3	6
604	Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. Analytical Chemistry, 2021, 93, 11108-11115.	6.5	6
605	Degeneration of the centrÃ© medianâ€“parafascicular complex in Parkinson's disease. Annals of Neurology, 2000, 47, 345-352.	5.3	6
606	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr Î±â€synuclein mutation. Annals of Neurology, 2001, 49, 313-319.	5.3	6
607	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. Frontiers in Neurology, 2021, 12, 743688.	2.4	6
608	Thalamic and Cerebellar Regional Involvement across the ALSâ€“FTD Spectrum and the Effect of C9orf72. Brain Sciences, 2022, 12, 336.	2.3	6
609	A small molecule toll-like receptor antagonist rescues Î±-synuclein fibril pathology. Journal of Biological Chemistry, 2022, 298, 102260.	3.4	6
610	Utility of the Addenbrookeâ€™s Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. Brain Communications, 2022, 4, .	3.3	6
611	Prediction of minimal erythema dose with a reflectance melanin meter. British Journal of Dermatology, 1997, 136, 714-718.	1.5	5
612	Genetics of Parkinson's Disease. , 2007, , 663-697.		5

#	Article	IF	Citations
613	Early in vivo Effects of the Human Mutant Amyloid-Î² Protein Precursor (hAÎ²PPSwInd) on the Mouse Olfactory Bulb. Journal of Alzheimer's Disease, 2015, 49, 443-457.	2.6	5
614	<scp>I</scp>ncreased aneuploidy is not a universal feature across Î±â€synucleinopathies. Movement Disorders, 2017, 32, 475-476.	3.9	5
615	Lipid content determines aggregation of neuromelanin granules in vitro. , 2007, , 35-38.		5
616	Neurotransmitter Changes in Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1995, , 199-219.	0.2	5
617	Overlap between Central and Peripheral Transcriptomes in Parkinsonâ€™s Disease but Not Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 5200.	4.1	5
618	Sunscreens and vitamin E provide some protection to the skin immune system from solarâ€simulated UV radiation. Australasian Journal of Dermatology, 1998, 39, 71-75.	0.7	4
619	Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. Neurocase, 2006, 12, 81-90.	0.6	4
620	Pigmentation in the human brain and risk of Parkinson's disease. Annals of Neurology, 2010, 67, 553-554.	5.3	4
621	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. Future Neurology, 2013, 8, 347-357.	0.5	4
622	Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathology and Applied Neurobiology, 2015, 41, 681-685.	3.2	4
623	Deletion of Alzheimerâ€™s Disease Risk Gene ABCA7 Alters White Adipose Tissue Development and Leptin Levels. Journal of Alzheimer's Disease Reports, 2017, 1, 237-247.	2.2	4
624	Are mutations in MAPT associated with GGT type III?. Neuropathology and Applied Neurobiology, 2020, 46, 406-409.	3.2	4
625	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
626	Globular glial tauopathy with a mutation in MAPT and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. Acta Neuropathologica, 2021, 141, 791-794.	7.7	4
627	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Annals of Neurology, 2000, 47, 718-728.	5.3	4
628	Alpha Synuclein in Parkinsonâ€™s Disease. , 2014, , 691-726.		4
629	Diagnostic evaluation of the substantia nigra. Neuropathology and Applied Neurobiology, 1996, 22, 228-232.	3.2	4
630	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. Journal of Histotechnology, 1996, 19, 33-38.	0.5	4

#	Article	IF	Citations
631	ESHRD: deconvolution of brain homogenate RNA expression data to identify cell-type-specific alterations in Alzheimerâ€™s disease. Aging, 2020, 12, 4124-4162.	3.1	4
632	Examining the presence and nature of delusions in Alzheimerâ€™s disease and frontotemporal dementia syndromes. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	4
633	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. Npj Parkinson's Disease, 2022, 8, 16.	5.3	4
634	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	4
635	Sex-specific lipid dysregulation in the Abca7 knockout mouse brain. Brain Communications, 2022, 4, .	3.3	4
636	Diagnostic evaluation of the substantia nigra. Neuropathology and Applied Neurobiology, 1996, 22, 228-232.	3.2	3
637	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. Journal of Clinical Neuroscience, 1999, 6, 149-154.	1.5	3
638	Clarifying Lewy-body parkinsonism with visual hallucinations. Lancet Neurology, The, 2005, 4, 588-589.	10.2	3
639	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. Parkinsonism and Related Disorders, 2006, 12, 309-313.	2.2	3
640	P1-039: MAPT METHYLATION IN ALZHEIMER'S DISEASE. , 2014, 10, P317-P318.		3
641	Reply: Will FTLD-tau work for all when FTDP-17 retires?. Brain, 2018, 141, e63-e63.	7.6	3
642	Letter to the Editor. Journal of Neuropathology and Experimental Neurology, 2019, 78, 975-977.	1.7	3
643	The Role of Astrocytes in Parkinsonâ€™s Disease. , 2014, , 127-144.		3
644	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinsonâ€™s disease?. Brain, 2020, 143, 3518-3521.	7.6	3
645	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. Neurobiology of Aging, 2022, 112, 122-128.	3.1	3
646	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. NeuroImage: Clinical, 2022, 33, 102958.	2.7	3
647	Topical retinoic acid inhibits changes in Langerhans cell density during carcinogenesis. In Vivo, 1993, 7, 271-6.	1.3	3
648	The emergence of proto-objects in complex visual hallucinations. Behavioral and Brain Sciences, 2005, 28, 767-768.	0.7	2

#	Article	IF	Citations
649	Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Movement Disorders, 2013, 28, 1804-1806.	3.9	2
650	Misfolded proteins in <scp>H</scp>untington disease fetal grafts: Further evidence of cellâ€toâ€cell transfer?. Annals of Neurology, 2014, 76, 20-21.	5.3	2
651	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
652	The differentiation of progressive supranuclear palsy. Neurodegenerative Disease Management, 2015, 5, 385-388.	2.2	2
653	Authors' response to a reply to â€˜A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipientsâ€™. British Journal of Dermatology, 2017, 176, 552-553.	1.5	2
654	001â€…Altered interval timing as a novel marker of cognitive fluctuations in lewy body dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A1.1-A1.	1.9	2
655	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. Aging Brain, 2021, 1, 100011.	1.3	2
656	Anteriorâ€posterior electrophysiological activity characterizes Parkinsonian visual misperceptions. Neurology and Clinical Neuroscience, 2021, 9, 312-318.	0.4	2
657	Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease. Frontiers in Immunology, 2021, 12, 736260.	4.8	2
658	Ascending Noradrenergic and Serotonergic Systems in the Human Brainstem. Advances in Behavioral Biology, 1995, , 155-171.	0.2	2
659	Pattern of Midbrain Pathology in Different Parkinsonian Syndromes. Advances in Behavioral Biology, 1996, , 441-444.	0.2	2
660	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. Bio-protocol, 2020, 10, e3572.	0.4	2
661	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia. Cortex, 2022, 149, 73-84.	2.4	2
662	An adaptive measure of visuospatial impairment in Dementia with Lewy Bodies. Movement Disorders Clinical Practice, 0, , .	1.5	2
663	Motor deficits associated with changes in Â-amyloid in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 475-476.	1.9	1
664	Unusual Î±â€synuclein and cerebellar pathologies in a case of hereditary myoclonusâ€dystonia without <scp>SGCE</scp> mutation. Neuropathology and Applied Neurobiology, 2015, 41, 837-842.	3.2	1
665	Reply: Lysosomal dysfunction in Parkinsonâ€™s disease. Brain, 2015, 138, e340-e340.	7.6	1
666	A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1122-1126.	1.7	1

#	Article	IF	Citations
667	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. Neurobiology of Aging, 2021, 107, 11-20.	3.1	1
668	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. , 2000, 47, 718.		1
669	Variable Phenotype of Alzheimer's Disease with Spastic Paraparesis. Research and Perspectives in Alzheimer's Disease, 2005, , 73-92.	0.1	1
670	Cytoarchitecture and Chemistry of Midbrain Dopaminergic Cell Groups. Advances in Behavioral Biology, 1995, , 115-127.	0.2	1
671	Carcinogen-Treated Skin Allografts Rejected by T Lymphocytes Specific for Class I but Not Class II MHC Antigens. Cellular Immunology, 1993, 151, 291-299.	3.0	0
672	ORGANIZATION: PYRAMIDAL AND EXTRAPYRAMIDAL SYSTEM. , 2007, , 396-401.		0
673	O.064 Thalamic changes in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S17.	2.2	0
674	P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain. Parkinsonism and Related Disorders, 2009, 15, S164.	2.2	0
675	A23â€...Changes in key hypothalamic neuropeptide populations in Huntington's Disease revealed by neuropathological analyses. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A7.3-A8.	1.9	0
676	Reply to: â€œBeing too inclusive about synuclein inclusionsâ€• Nature Medicine, 2010, 16, 961-961.	30.7	0
677	Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinsonâ€™s Disease. , 2014, , 15.		0
678	H04 Gene Expression Changes In Emotion And Metabolism Regulating Neuropeptide Systems In The Hypothalamus In Clinical Huntington Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A53-A53.	1.9	0
679	Progressive supranuclear palsy finally has a clinically measureable Â abnormality. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 241-241.	1.9	0
680	The hummingbird identifies psp among patients with non-fluent primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.19-e1.	1.9	0
681	[S3â€“01â€“01]: MIXED PATHOLOGY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P877.	0.8	0
682	White matter changes in frontotemporal dementia and the C9ORF72 gene expansions. Journal of the Neurological Sciences, 2017, 381, 803.	0.6	0
683	P1â€405: VISUAL ASSESSMENT OF Î²â€AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. Alzheimer's and Dementia, 2018, 14, P459.	0.8	0
684	A52â€...SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways. , 2018, , .		0

#	Article	IF	Citations
685	013â€…Lipid metabolism and body composition in frontotemporal dementia-amyotrophic lateral sclerosis spectrum: effect on survival and disease progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A6.3-A7.	1.9	0
686	110â€…Atrophy of the mediodorsal thalamus is associated with visual hallucinations in lewy body diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A43.3-A44.	1.9	0
687	060â€…Impaired color discrimination is associated with hallucinations in dementia with lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A19.3-A20.	1.9	0
688	037â€…Frontotemporal dementia or frontal variant alzheimerâ€™s disease? A case series. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A13.1-A13.	1.9	0
689	093â€…How to diagnose lewy body dementia? Prevalence and underlying relationship between clinical and neuropsychological features of DLB. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A30.1-A30.	1.9	0
690	095â€…Predicting parkinsonâ€™s and dementia with lewy bodies (pre-D) research study â€“ a sydney-based longitudinal biobanking program. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A30.3-A31.	1.9	0
691	Author response: The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology, 2020, 94, 283-283.	1.1	0
692	Invited Reply to: â€œInstrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorderâ€• Movement Disorders, 2020, 35, 195-196.	3.9	0
693	The aging brain and brain banking. , 2021, , 103-112.		0
694	Which Basal Ganglia Surgical Targets Ameliorate Parkinsonian Symptoms?. Advances in Behavioral Biology, 2002, , 533-542.	0.2	0
695	Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System. Advances in Behavioral Biology, 1995, , 129-153.	0.2	0
696	Thalamic and Cortical Changes in Parkinsonian Disorders. , 2005, , 415-424.		0
697	Physiologic and Neurotoxic Properties of AÎ² Peptides. , 2007, , 179-197.		0
698	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of Î±-Synuclein Autoantibodies in Human Plasma. Bioconjugate Chemistry, 2022, , .	3.6	0
699	Schizotypal traits across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum: pathomechanistic insights. Journal of Neurology, 2022, , 1.	3.6	0
700	Presence of coâ€pathology in sporadic earlyâ€onset Alzheimer disease versus dominantly inherited Alzheimer disease. Alzheimer's and Dementia, 2021, 17, e055045.	0.8	0